Evaluation of Bimekizumab in PsA At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv

Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR

• Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomi…
• https://x.com/RichardPAConway/status/1858572630426874065/photo/1

A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m

• https://x.com/ericdeinmd/status/1858556716075339953/photo/1

Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq

• Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data f…
• https://x.com/RichardPAConway/status/1858553252964692082/photo/1

In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%) This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts. @rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I

• https://x.com/RHEUMarampa/status/1858547480293450040/photo/1

A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes Key findings: - Significant weight loss after starting IL17i, IL23i, and csDMARDs. - TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn

• https://x.com/i/web/status/1858548221381075437
• https://x.com/synovialjoints/status/1858548221381075437/photo/1

A study evaluating the effectiveness of Direct-to-Patient (D2P) screening for psoriatic arthritis (PsA) in psoriasis patients. Key findings: - 30% response rate from 825 patients; 13% screened positive. - 75% of referrals deemed appropriate, with one-third receiving a new PsA… https://t.co/bcQN6KkC8m https://t.co/zogI2PYvtO

• https://x.com/i/web/status/1858544445156962383
• https://x.com/synovialjoints/status/1858544445156962383/photo/1